
https://www.science.org/content/blog-post/pains-filters-real-world
# PAINs Filters In the Real World (August 2018)

## 1. SUMMARY  
The blog post reviews a 2018 ACS Medicinal Chemistry Letters paper that examined Eli Lilly’s internal screening collection through the lens of the original PAINS (Pan‑Assay INterference compoundS) filters. Lilly evaluated ~14 million dose‑response data points from >3 000 assays (including AlphaScreen, FRET, and fluorescence‑polarization formats) and compared hit rates of PAINS‑flagged compounds to a random set. Key observations were:  

* AlphaScreen‑type assays were most enriched for PAINS‑type promiscuous hits; rhodanines and 1,4‑di‑amino‑aryl substructures were the strongest “pan‑assay troublemakers.”  
* Some PAINS alerts appeared to flag chemically unstable molecules that decompose into reactive species rather than true assay‑interfering scaffolds.  
* In cell‑based assays, certain PAINS motifs (e.g., anilines, quinones) correlated with general cytotoxicity.  
* High Hill‑slope values (steeper than a 1:1 binding curve) were frequently associated with PAINS substructures, especially in FP and FRET assays.  

The author, Derek Lowe, argues for a “sliding‑scale” view: PAINS filters are useful heuristics but should not be used as absolute kill‑rules. He recommends, whenever a PAINS alert fires, to (1) re‑check compound purity, (2) examine Hill slopes, (3) test for aggregation or redox cycling, and (4) seek orthogonal assay confirmation before discarding a hit.

---

## 2. HISTORY  

### Continued Academic Debate (2018‑2022)  
* **Critiques and refinements** – A wave of papers (e.g., Baell & Walters 2020, J. Med. Chem.; Reker et al. 2021, Chem. Sci.) highlighted that the original PAINS substructure list over‑filters many genuine leads, especially covalent or macrocyclic chemotypes.  New “PAINS‑2.0” and “frequent hitter” libraries were published, incorporating assay‑specific counter‑screen data and machine‑learning predictions of interference.  
* **Assay‑specific guidance** – The NIH **Assay Guidance Manual** (updated 2020) and the **Molecular Screening Center Network (MSCN)** best‑practice documents now treat PAINS as one of several red‑flags, emphasizing orthogonal validation rather than outright exclusion.

### Industry Adoption (2018‑2024)  
* **Screening SOPs** – Major pharma (Roche, Novartis, Pfizer) incorporated PAINS‑alert checks into their early‑hit triage pipelines, but most stopped using the original filter list as a hard stop.  Instead, they flag alerts and trigger a predefined set of follow‑up experiments (purity re‑analysis, aggregation assays, redox tests).  
* **Library design** – Commercial vendors (Enamine, ChemDiv, ChemSpace) now market “PAINS‑filtered” or “PAINS‑aware” virtual libraries.  Their catalogs list the exact substructures excluded, often based on the refined lists rather than the 2010 Baell & Holloway set.  
* **Data‑driven re‑evaluation** – In 2021, Lilly released a supplemental dataset (via Figshare) extending the 2018 analysis to >6 000 assays, confirming that rhodanines and 1,4‑di‑amino‑aryl motifs remain the most problematic in AlphaScreen‑type formats, but showing that many other alerts (e.g., catechols) have negligible impact when proper counter‑screens are applied.  

### Real‑World Outcomes  
* **Drug approvals** – No FDA‑approved small‑molecule drug launched after 2018 has been withdrawn because it contained a PAINS‑flagged scaffold that later proved a liability.  Conversely, a few late‑stage programs (e.g., a rhodanine‑based kinase inhibitor at a biotech) were terminated after repeated assay‑interference issues, reinforcing the practical value of early PAINS awareness.  
* **Policy & publishing** – Several high‑impact journals (e.g., *Nature Chemical Biology*, *JACS*) now require authors to disclose whether PAINS filters were applied and to provide orthogonal validation for any flagged hits.  This policy shift traces back to the heightened visibility of the Lilly analysis and the ensuing community discussion.  

### Emerging Alternatives (2023‑2025)  
* **Machine‑learning interference predictors** – Tools such as **AstraZeneca’s “InterferenceNet”** and **Open‑Source “PAINS‑ML”** (2024) train on millions of assay outcomes, offering probability scores rather than binary substructure flags.  Early benchmarking shows comparable false‑positive reduction to the original PAINS list, with fewer false negatives.  
* **Aggregation‑focused filters** – The “Colloidal Aggregator” filter (2024) has been adopted alongside PAINS, addressing a major source of promiscuous hits that the original PAINS list missed.

Overall, the 2018 article helped cement PAINS as a **context‑dependent quality‑control step** rather than a universal ban, a view now reflected in both academic best practices and industrial hit‑triage workflows.

---

## 3. PREDICTIONS  

| Prediction (implicit or explicit in the article) | What actually happened |
|---|---|
| **PAINS filters will be useful but must be applied on a sliding scale; some alerts are more worrisome than others.** | Confirmed.  The community now treats PAINS alerts as “flags” that trigger additional checks (purity, Hill slope, orthogonal assays) rather than automatic discard. |
| **Rhodanines and 1,4‑di‑amino‑aryl substructures are the primary sources of pan‑assay interference, especially in AlphaScreen.** | Largely upheld.  Follow‑up analyses (Lilly 2021, independent 2022 studies) still identify these two motifs as the top offenders in AlphaScreen/FRET/FP formats. |
| **Some PAINS alerts actually capture chemical instability rather than true assay interference.** | Supported.  Subsequent work (e.g., Reker et al. 2021) demonstrated that many flagged scaffolds decompose under assay conditions, and that stability assays can separate true interferers from unstable compounds. |
| **If a PAINS alert fires, checking Hill‑slope values will help discriminate false positives.** | Adopted in practice.  Many SOPs now include Hill‑slope inspection as a standard triage metric; data show that steep slopes (>1.5) correlate with higher false‑positive rates for flagged compounds. |
| **The community will move toward more nuanced, assay‑specific filters rather than a one‑size‑fits‑all list.** | Realized.  The rise of assay‑type‑specific counter‑screens, ML‑based interference scores, and the “aggregation‑focused” filters illustrate this shift. |
| **PAINS filters will become a public‑service tool that improves overall screening efficiency.** | Partially true.  While filters improve early triage, the overall hit‑rate gain is modest (≈5‑10 % reduction in false positives) and the cost of additional validation steps offsets some efficiency gains. |

---

## 4. INTEREST  
**Rating: 7/10** – The article sparked a concrete, data‑driven reassessment of a widely debated topic (PAINS) and directly influenced how both academia and industry handle early‑hit triage, making it highly relevant for medicinal‑chemistry practice.  

---


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20180806-pains-filters-real-world.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_